Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic draws subpoena

This article was originally published in The Gray Sheet

Executive Summary

Documents relating to the firm's cardiac rhythm management devices are subpoenaed by the Office of Inspector General for the Department of Health and Human Services in the district of California, Medtronic discloses in a quarterly financial report filed Dec. 9 with the Securities and Exchange Commission. Related documents include "revenue, sales, marketing and promotional documents, documents relating to reimbursement communications to customers pertaining to the devices, documents relating to scientific studies and registries pertaining to the devices, and documents relating to payments or items of value provided to customers," Medtronic explains. The firm says it will comply with the subpoena, which it received on Sept. 16. Medtronic received a separate subpoena in June from the New Jersey attorney general's office as part of an investigation into industry ties to clinical trial investigators (1"The Gray Sheet" Aug. 10, 2009)

You may also be interested in...



New Jersey AG's Targets: J&J/DePuy, Biomet, Stryker, Medtronic And...

Johnson & Johnson/DePuy is the latest of four orthopedic device makers to acknowledge receipt of a subpoena from the New Jersey attorney general's office as part of an investigation into industry ties to clinical trial investigators

COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Topics

UsernamePublicRestriction

Register

MT028275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel